Insulin-Like Growth Factor 1 Receptor and Response to Anti-IGF1R Antibody Therapy in Osteosarcoma
Yu Cao(Albert Einstein College of Medicine), Richard Görlick(Albert Einstein College of Medicine), Michael Roth(The University of Texas MD Anderson Cancer Center), Kristofer Montoya(Children's Hospital at Montefiore), David S. Geller(Albert Einstein College of Medicine), Sajida Piperdi(Albert Einstein College of Medicine), Rebecca Sowers(Albert Einstein College of Medicine), Peter J. Houghton(St. Jude Children's Research Hospital), E. Anders Kolb(Alfred I. duPont Hospital for Children), Pulivarthi H. Rao(Children's Cancer Center), Jonathan Gill(Albert Einstein College of Medicine)
Cited by 47
Related Papers
K <sup>+</sup> Channel Mutations in Adrenal Aldosterone-Producing Adenomas and Hereditary Hypertension
|Science|2011|981
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort
|European Journal of Cancer|2019|724
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial
|The Lancet Oncology|2016|537
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial
|Journal of Clinical Oncology|2015|419
Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia
|Journal of Clinical Oncology|2015|383